meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
1
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
mHNSCC - L2 - all population
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open